Home > Boards > Stock Clubs > Technical Analysis > QualityStocks

QualityStocksNewsBreaks – Pressure BioSciences, Inc. (PBIO) to Host

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
QualityStocks Member Profile
 
Followed By 424
Posts 43,302
Boards Moderated 2
Alias Born 05/08/06
160x600 placeholder
QualityStocks   Wednesday, 07/08/20 07:42:10 PM
Re: None
Post # of 26891 
Compensated Awareness Post - View Disclaimer
QualityStocksNewsBreaks – Pressure BioSciences, Inc. (PBIO) to Host Teleconference to Discuss Q1 2020 Results and Provide Business Update

Pressure BioSciences (OTCQB: PBIO) on Tuesday announced that it will host a teleconference to discuss its first quarter 2020 financial results and to provide a business update, including the Company’s progress made in the development of its Ultra Shear Technology(TM) (“UST(TM)) Platform and in the pending merger of PBI, Cannaworx, and SkinScience Labs. The call is scheduled to take place at 4:30 p.m. Eastern Time on July 8, 2020. Interested parties may join the conference by dialing (844) 602-0380 (North America) or (862) 298-0970 (International) and entering verbal passcode: PBI First Quarter 2020 Financial Call & Business Update. For those unable to participate in the live teleconference, a replay will be available beginning Thursday, July 9, 2020, and will be accessible for 30 days via telephone and the Company’s website.

To view the full press release, visit http://ibn.fm/9486F

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Its products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The Company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences